Searchable abstracts of presentations at key conferences in endocrinology

ea0032p750 | Obesity | ECE2013

Osteocalcin: more than a bone marker: the Odense Androgen Study

Nielsen Torben Leo , Brixen Kim , Hermann Anne Pernille , Andersen Marianne

Introduction: The osteoblast derived bone formation marker osteocalcin has been reported to decrease adipose tissue in mice. In elderly men, osteocalcin was reported to correlate inversely with fat mass.Aim: To examine the relationship between osteocalcin and regional fat depots.Method: The Odense Androgen Study is a population-based, cross-sectional study of 779 randomly selected men aged 20–29 years. Total, central, upper ex...

ea0035p618 | Female reproduction | ECE2014

Changes in body composition following 12 months randomized treatment with metformin vs oral contraceptives vs combined treatment in polycystic ovary syndrome

Glintborg Dorte , Altinok Magda , Mumm Hanne , Hermann Anne Pernille , Ravn Pernille , Andersen Marianne

Background: Central obesity in polycystic ovary syndrome (PCOS) is associated with increased inflammatory markers and increased risk for type 2 diabetes.Aim: To evaluate the long-term effects of metformin (M) and/or oral contraceptives (OC) on fat mass.Research design: Randomized, controlled study.Setting: Outpatient clinic.Methods: 90 patients with PCOS were randomized to 12 months M (...

ea0016s30.6 | Clinical highlights | ECE2008

Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial

Glintborg Dorte , Andersen Marianne , Hagen Claus , Heickendorff Lene , Hermann Anne Pernille

Background: PPARγ-agonist treatment may decrease bone mineral density (BMD) in postmenopausal women. The hypothesis that premenopausal women are relatively protected from mineral loss during PPARγ-agonist treatment has not been evaluated in clinical studies.Aim: To investigate the effect of pioglitazone on BMD and bone turnover markers in patients with polycystic ovary syndrome (PCOS).Methods: Thirty premenopausal PCOS pa...

ea0014p231 | (1) | ECE2007

Pioglitazone treatment significantly decreases 5-alpha reductase activity and improves metabolic risk factors in PCOS

Glintborg Dorte , Hermann Anne Pernille , Hagen Claus , Veldhuis Johannes , Schmedes Anne , Frystyk Jan , Flyvbjerg Allan , Andersen Marianne

Objective: To investigate the effect of pioglitazone on cortisol metabolism in PCOS.Design: Thirty insulin resistant PCOS patients were randomized to either 16 weeks of pioglitazone (30 mg/day) or placebo treatment. Before and after intervention, patients underwent 24 h 20 min.-integrated blood sampling for measurement of cortisol and 24 h excretion of cortisol, cortisone and steroid metabolites (cortisol, corticosteron, androgen, and 17-hydroxyprogester...